2013-01-23 15:02:19 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to PT Millennium Pharmacon Int. Tbk and produced a Rating Update Report, rating the company's attractiveness to long-term investors.

Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering PT Millennium Pharmacon Int. Tbk (SDPC). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential PT Millennium Pharmacon Int. Tbk investor.

Report Summary: PT Millennium Pharmacon Int. Tbk is an average quality company with a neutral outlook. PT Millennium Pharmacon Int. Tbk has weak business growth and is run by passable management. The trend in PT Millennium Pharmacon Int. Tbk fair value exchange rate against its closest rated-competitor, PT Mustika Ratu Tbk, has been stable over the past 2 weeks. When compared to its closest competitor, PT Millennium Pharmacon Int. Tbk shows similar overvaluation and is equally likely to

underperform the market.

The 3-page report breaks down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of PT Millennium Pharmacon Int. Tbk for long-term investors.

The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
www.sadifanalytics.com/stockmarks/company-ru-49-SDPC

About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.